Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Profund Advisors LLC

Profund Advisors LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 96.1% during the 4th quarter, HoldingsChannel reports. The firm owned 76,224 shares of the biotechnology company’s stock after purchasing an additional 37,350 shares during the period. Profund Advisors LLC’s holdings in Sarepta Therapeutics were worth $1,640,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of SRPT. iSAM Funds UK Ltd purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $25,000. Ancora Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,000 shares during the last quarter. Allworth Financial LP increased its position in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares during the period. Parallel Advisors LLC increased its position in Sarepta Therapeutics by 165.3% in the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,256 shares during the period. Finally, Atlantic Union Bankshares Corp purchased a new stake in Sarepta Therapeutics during the 3rd quarter valued at approximately $48,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, March 26th. Citigroup boosted their target price on Sarepta Therapeutics from $9.00 to $13.00 and gave the company a “sell” rating in a report on Thursday, March 26th. Wedbush increased their price target on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 26th. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Loop Capital set a $25.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $27.71.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares in the company, valued at approximately $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is owned by corporate insiders.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $17.12 on Thursday. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The stock’s 50 day moving average is $20.02 and its two-hundred day moving average is $20.00. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $44.14. The firm has a market capitalization of $1.81 billion, a PE ratio of -17.83, a P/E/G ratio of 0.19 and a beta of 0.26.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. The business had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted ($3.42) EPS. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.69 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.